GRAY Stock Overview
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve.
+ 1 more risk
Graybug Vision Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.98|
|52 Week High||US$4.87|
|52 Week Low||US$0.72|
|1 Month Change||-0.41%|
|3 Month Change||-19.01%|
|1 Year Change||-79.63%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-94.06%|
Recent News & Updates
We're Keeping An Eye On Graybug Vision's (NASDAQ:GRAY) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|GRAY||US Pharmaceuticals||US Market|
Return vs Industry: GRAY underperformed the US Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: GRAY underperformed the US Market which returned -21.2% over the past year.
|GRAY Average Weekly Movement||13.8%|
|Pharmaceuticals Industry Average Movement||11.9%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: GRAY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: GRAY's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company’s lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.
Graybug Vision Fundamentals Summary
|GRAY fundamental statistics|
Is GRAY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GRAY income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.62|
|Net Profit Margin||0.00%|
How did GRAY perform over the long term?See historical performance and comparison
Is GRAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GRAY?
Other financial metrics that can be useful for relative valuation.
|What is GRAY's n/a Ratio?|
Price to Book Ratio vs Peers
How does GRAY's PB Ratio compare to its peers?
|GRAY PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
VRPX Virpax Pharmaceuticals
RVPH Reviva Pharmaceuticals Holdings
PTPI Petros Pharmaceuticals
TMBR Timber Pharmaceuticals
GRAY Graybug Vision
Price-To-Book vs Peers: GRAY is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.9x).
Price to Earnings Ratio vs Industry
How does GRAY's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: GRAY is good value based on its Price-To-Book Ratio (0.4x) compared to the US Pharmaceuticals industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is GRAY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.4x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate GRAY's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of GRAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GRAY's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GRAY's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GRAY's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Graybug Vision forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRAY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GRAY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GRAY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GRAY's revenue (43.2% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: GRAY's revenue (43.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GRAY's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Graybug Vision performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRAY is currently unprofitable.
Growing Profit Margin: GRAY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GRAY is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare GRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Return on Equity
High ROE: GRAY has a negative Return on Equity (-61.36%), as it is currently unprofitable.
Discover strong past performing companies
How is Graybug Vision's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GRAY's short term assets ($58.2M) exceed its short term liabilities ($4.2M).
Long Term Liabilities: GRAY's short term assets ($58.2M) exceed its long term liabilities ($102.0K).
Debt to Equity History and Analysis
Debt Level: GRAY is debt free.
Reducing Debt: GRAY has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRAY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GRAY has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 0.3% each year.
Discover healthy companies
What is Graybug Vision current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GRAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GRAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GRAY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GRAY's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GRAY has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fred Guerard (49 yo)
Dr. Frederic Guerard, Pharm D., also known as Fred, has been Director at Lenz Therapeutics, Inc. since 2021. Dr. Guerard has been President, Chief Executive Officer and Director at Graybug Vision, Inc. sin...
CEO Compensation Analysis
Compensation vs Market: Fred's total compensation ($USD4.41M) is above average for companies of similar size in the US market ($USD800.58K).
Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.
Experienced Management: GRAY's management team is considered experienced (2.1 years average tenure).
Experienced Board: GRAY's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Graybug Vision, Inc.'s employee growth, exchange listings and data sources
- Name: Graybug Vision, Inc.
- Ticker: GRAY
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$20.936m
- Shares outstanding: 21.36m
- Website: https://www.graybug.vision
Number of Employees
- Graybug Vision, Inc.
- 203 Redwood Shores Parkway
- Suite 620
- Redwood City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/02 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.